文献速递类风湿关节炎

改善病情抗风湿药对类风湿关节炎相关口腔微生物的体外抗菌活性评价

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora.
PubMed 文献 · RMD Open · 2021-01-01

该体外研究筛查了改善病情抗风湿药(DMARDs)对与类风湿关节炎(RA)相关的口腔微生物的抗菌活性。结果显示,金硫苹果酸钠和柳氮磺吡啶具有广谱抗菌活性但仅见于超治疗浓度,甲氨蝶呤仅对具核梭杆菌和草绿色链球菌有抗菌活性,且对链球菌的MIC在治疗可及范围内。

要点

  • 甲氨蝶呤对草绿色链球菌的MIC为0.5-15 µg/mL,处于治疗可及浓度范围。
  • 柳氮磺吡啶仅在高出治疗浓度时对RA相关口腔微生物有抗菌活性。
  • 金硫苹果酸钠具广谱抗菌活性,但MIC为18至>280 µg/mL,属超治疗浓度。

核心结论

  • 甲氨蝶呤、柳氮磺吡啶和金硫苹果酸钠对多种RA相关口腔病原体显示抗菌活性,但仅甲氨蝶呤的抗菌活性在治疗可及浓度范围内具有相关性。

研究设计与样本

  • 体外研究,采用琼脂扩散法筛查DMARDs对RA相关口腔微生物的抗菌活性,再用肉汤稀释法测定有活性药物的最低抑菌浓度(MIC)。

主要发现

  • 金硫苹果酸钠和柳氮磺吡啶显示广谱抗菌活性,MIC分别为18至>280 µg/mL和150至>600 µg/mL。
  • 甲氨蝶呤仅对具核梭杆菌和草绿色链球菌有抗菌活性,MIC分别为3.75至>30 µg/mL和0.5-15 µg/mL。
  • 其他受试DMARDs在琼脂扩散筛查中未显示抗菌活性。

关键数值与推荐

  • 甲氨蝶呤对草绿色链球菌的MIC为0.5-15 µg/mL,处于治疗可及浓度范围。
  • 金硫苹果酸钠对RA相关口腔微生物的MIC为18至>280 µg/mL。
  • 柳氮磺吡啶对RA相关口腔微生物的MIC为150至>600 µg/mL。
  • 甲氨蝶呤对具核梭杆菌的MIC为3.75至>30 µg/mL。

临床怎么用

  • 甲氨蝶呤对草绿色链球菌的抗菌活性在治疗浓度范围内,可能与其治疗RA的效应部分相关。
  • 柳氮磺吡啶的抗菌活性仅见于远高于治疗浓度的水平,全身用药时该效应可能有限。

局限性

  • 本研究为体外实验,抗菌活性结果不能直接推广至体内临床效应。
  • 抗菌活性具有高度物种依赖性,且未评估药物对整体人类微生物组的综合影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In the past, the human microbiome has consistently been associated with rheumatoid arthritis (RA) and disease activity. Here, we investigate the antimicrobial activity of disease-modifying antirheumatic drugs (DMARDs) against typical representatives of the oral microflora that have been associated with RA. METHODS: DMARDs were screened for antimicrobial activity against bacteria that are associated with the pathogenesis of the disease and/or frequently isolated from the oral microflora of patients with RA. Screening was done by an agar diffusion assay and minimum inhibitory concentrations (MICs) of antimicrobial active substances were then determined by broth dilution. RESULTS: Aurothiomalate and sulfasalazine demonstrated broad-spectrum antimicrobial activity, but with MICs ranging from 18 to >280 µg/mL and 150 to >600 µg/mL, respectively, only at supratherapeutic concentrations. Methotrexate showed antimicrobial activity only against Fusobacterium nucleatum and Viridans streptococci. The corresponding MICs were 3.75 to >30 µg/mL and 0.5-15 µg/mL, respectively, thus at least for streptococci, within the therapeutically achievable range. No other DMARD tested showed antimicrobial activity in the agar diffusion screening assay. CONCLUSION: Methotrexate, sulfasalazine and aurothiomalate showed antimicrobial activity against a broad spectrum of RA associated pathogens of the oral microflora. While methotrexate showed relevant antimicrobial activity, and to a more limited extent aurothiomalate, sulfasalazine was active only at far supratherapeutic systemic concentrations. Nevertheless, given the highly species-dependent antimicrobial activity and the multiple ways it can affect the human microbiome, our results suggest a link between antimicrobially active antirheumatic drugs and their potential effect in the treatment of RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kussmann M, Obermueller M, Spettel K, et al. In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora. RMD Open. 2021. PMID: 34588273. doi:10.1136/rmdopen-2021-001737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。